Cost per patient and potential budget implications of denosumab compared with zoledronic acid in adults with bone metastases from solid tumours who are at risk of skeletal-related events: An analysis for Austria, Sweden and Switzerland

European Journal of Hospital Pharmacy

Volumn 20, Issue 4, 2013, Pages 227-231

  Lothgren, Mickael ^a   Ribnicsek, Erna ^a   Schmidt, Louise ^b   Habacher, Wolfgang ^b   Lundkvist, Jonas ^c   Pfeil, Alena M ^d   Biteeva, Irina ^a   Vrouchou, Polina ^a   Bracco, Andrea ^a  

^a AMGEN INC   (United States)

^b JOANNEUM RESEARCH   (Austria)

^c Health Economics and Reimbursement   (Sweden)

^d UNIVERSITY OF BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

DENOSUMAB; ZOLEDRONIC ACID;

ARTICLE; BONE METASTASIS; DRUG COST; DRUG EFFICACY; ECONOMIC ASPECT; HEALTH CARE COST; HUMAN; PATIENT CARE; PHASE 3 CLINICAL TRIAL (TOPIC); PRESCRIPTION; SOLID TUMOR;

EID: 84880580893     PISSN: 20479956     EISSN: 20479964     Source Type: Journal    
DOI: 10.1136/ejhpharm-2012-000235     Document Type: Article

References (28)

1. Roodman GD. Mechanisms of bone metastasis. N Engl J Med 2004;350:1655-1654.
2. Rubens RD. Bone metastases-the clinical problem. Eur J Cancer 1998;34:210-213.
3. Weinfurt KP, Li Y, Castel LD, et al. The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. Ann Oncol 2005;16:579-584.
4. Bahl A, Hoefeler H, Duran I, et al. Health resource utilisation (HRU) associated with skeletal-related events (SREs) in patients with bone metastases (BM): tesults of a prospective multinational observational study. J Clin Oncol 2011;29;15(Suppl): e16523.
5. Gunther O, Body JJ, Sleeboom H, et al. Cost of skeletal complications from bone metastases: results from a retrospective European Study. Support Care Cancer 2012.
6. European Medicines Agency. Zometa (zoledronic acid): summary of product characteristics. 2012;20:s89.
7. Oglesby A, Sherif B, Odom D, et al. Time and costs associated with preparing and administering zoledronic acid in patients with breast or prostate cancer and metastatic bone disease. Commun Oncol 2009;6:494-502.
8. Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 2010;28:5132-5139.
9. Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011;377:813-822.
10. Henry D, Von Moos R, Hungria V, et al. Delaying skeletal-related events in a randomized phase III study of denosumab versus zoledronic acid in patients with advanced cancer. J Clin Oncol 2010;28(7):abstract 9133.
11. Kretzschmar A, Wiege T, Al-Batran SE, et al. Rapid and sustained influence of intravenous zoledronic Acid on course of pain and analgesics consumption in patients with cancer with bone metastases: a multicenter open-label study over 1 year. Support Cancer Ther 2007;4:203-210.
12. Monitor ETO. Electronic Tandem Oncology Monitor 2012.
13. European Medicines Agency. Denosumab (XGEVA) Summary of Product Characteristics. 2012.
14. Österreichische Sozialversicherung. Services und Informationen für Vertragspartner. 2012. http://www.sozialversicherung.at/portal27/portal/esvportal/channel_content/cmsWindow?action=2&p_menuid=2989&p_tabid=5 (accessed 1 Sep 2012).
15. Das Land Steiermark Landesgesetzblatt. 2009.
16. Bundesministerium für Gesundheit, Leistungsorientierte Krankenanstaltfinanzierungs (LKF) Modell 2011.
17. Akademiska hospital Uppsala. Price list for Medical care, 2010.
18. Price list Southeast Health Region. Price List, 2011.
19. TARMED. TarmedSuisse Online browser 2012. http://onb.tarmedsuisse.ch/ (accessed 12 March 2012).
20. BAG Analysenliste. 2012. http://www.bag.admin.ch/themen/krankenversicherung/00263/00264/04185/index.html?lang=de (accessed 12 March 2012).
21. Landesgesetzblatt DLS. Das Land Steiermark Landesgesetzblatt. 2009; LGBI Stück 14:(Nr 45 und 6 p.).
22. County council of Gävle. Price list. Clinical chemistry and transfusion medicine, 2010.
23. Santèsuisse. Taxpunktwerte Ärzte. 2011. http://www.santesuisse.ch/de/dyn_output.html?content.void=47323&SID=453aa58313aca45c6df830ca457da269&navid=753 (accessed 12 March 2012).
24. Delmore G, Biteeva I, Steinmann K, et al. Direct medical costs associated with skeletal-related events in Switzerland. Presented at ECHE. 2012.
25. Spezialitätenliste (SL) http://bag.e-mediat.net/SL2007.Web.External/ (accessed 12 March 2012).
26. Bundesamt für Statistik BFS. Krankenhausstatistik. Standarttabellen 2009. http://www.bfs.admin.ch/bfs/portal/de/index/themen/14/03/01/data/01.html (accessed 12 March 2012).
27. Hatoum HT, Lin SJ, Smith MR, et al. Zoledronic acid and skeletal complications in patients with solid tumors and bone metastases: analysis of a national medical claims database. Cancer 2008;113:1438-1435.
28. Cleeland CS, Patrick D, Fallowfield L, et al. Effects of Denosumab vs Zoledronic acid on pain in patients with advanced cancer and bone metastases: an integrated analysis of 3 Pivotal Trials. Ann Oncol 2010;21(Suppl. 8):viii 380 (1248P).